ArticleBriefings in bioinformatics2025
GRAPE: graph-regularized protein language modeling unlocks TCR-epitope binding specificity.
Article in Briefings in bioinformatics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Screening and identification of B-cell epitopes on the gH protein of varicella-zoster virus.Archives of microbiology · 2026Article
- Rpf-Toxo: A Preliminary Computationally Designed Dense Granule Antigen-Based Multi-Epitope Vaccine Against Toxoplasma gondii.Veterinary medicine and science · 2026Article
- DynaTCR: dynamic hard-negative ensemble graph learning improves TCR-epitope binding prediction.Bioinformatics (Oxford, England) · 2026Article
- DUET: a graph-based workflow for TCR-epitope prioritization and tumor-reactive T-cell identification.Briefings in bioinformatics · 2026Article
- TriDTI: tri-modal representation learning with cross-modal alignment for drug-target interaction prediction.Briefings in bioinformatics · 2026Article
- pCPPs-sADNN: predicting cell-penetrating peptides using self-attention based deep neural network.Scientific reports · 2025Article
- DMAGCL: A dual-masked adaptive graph contrastive learning framework for predicting circRNA-drug sensitivity.Frontiers in genetics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
T-cell receptor (TCR)-epitope binding prediction is critical for immunotherapies but remains challenged by sparse interaction networks and severe class imbalance in training data. Current graph neural network (GNN) approaches for predicting TCR-epitope binding (TEB) fail to address two key limitations: over-smoothing during message propagation in sparse TCR-epitope graphs and biased predictions toward dominant epitope-TCR pairs. Here, we present GRAPE (Graph-Regularized Attentive Protein Embeddings), a framework unifying spectral graph regularization and imbalance-aware learning. GRAPE first leverages protein language models (ESM-2) to generate evolutionary-informed TCR/epitope embeddings, constructing a topology-aware interaction graph. To mitigate over-smoothing, we introduce spectral graph regularization, explicitly constraining node feature smoothness to preserve discriminative patterns in sparse neighborhoods. Simultaneously, a dynamic edge reweighting module prioritizes unobserved TCR-epitope edges during graph propagation, coupled with a differentiable area under the ROC curve-maximization objective that directly optimizes for imbalance resilience. Extensive benchmarking on public datasets demonstrates that GRAPE significantly outperforms state-of-the-art methods in TEB prediction. This work establishes GRAPE as a robust framework for elucidating TCR-epitope interactions, with broad applications in immunology research and therapeutic design.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.